Kshama Mehta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kshama Mehta has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alex Wong
Agilent Technologies, Inc., Santa Clara, CA 95051, USA
1 shared publication - Ernice Blann
Division of Systems Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA
1 shared publication - Hong Fang
ICF International at FDA's National Center for Toxicological Research, 3900 NCTR Rd, Jefferson, AR 72079, USA
1 shared publication - Jim Collins
Agilent Technologies, Inc., Santa Clara, CA 95051, USA
1 shared publication - Lei Guo
U.S. Food and Drug Administration
1 shared publication - Leming Shi
National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079, USA
1 shared publication
Latest Publications
- Open Access
- 26 September 2006
- Published by Springer Nature in BMC Bioinformatics
- Vol. 7 (S2) , S18
Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists
Fibrates are a unique hypolipidemic drugs that lower plasma triglyceride and cholesterol levels through their action as peroxisome proliferator-activated receptor alpha (PPARα) agonists. The activation of PPARα leads to a cascade of events that result in the pharmacological (hypolipidemic) and adverse (carcinogenic) effects in rodent liver.
- 26 September 2006
- Published by Springer Nature in BMC Bioinformatics
- Vol. 7 (S2) , S18
Open AccessDifferential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists
Fibrates are a unique hypolipidemic drugs that lower plasma triglyceride and cholesterol levels through their action as peroxisome proliferator-activated receptor alpha (PPARα) agonists. The activation of PPARα leads to a cascade of events that result in the pharmacological (hypolipidemic) and adverse (carcinogenic) effects in rodent liver.